GlassScriptPhysician profile
Marcella Perez Jones
NPI 1043431208
$1,443.09
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2021: $32.68 · 2022: $43.82 · 2023: $997 · 2024: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.67 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $160.11 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $130.54 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $106.46 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $102.87 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $67.47 | 2023 | Rexulti |
| Abbott Laboratories | $61.27 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sunovion Pharmaceuticals INC. | $60.49 | 2019 | |
| Pfizer INC. | $56.39 | 2023 | |
| Glaxosmithkline, LLC. | $55.88 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $55.14 | 2023 | Xarelto |
| Amgen INC. | $36.45 | 2023 | Prolia, Evenity, Otezla |
| Allergan, INC. | $29.99 | 2019 | |
| Sumitomo Pharma America, INC. | $25.99 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $21.45 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.36 | 2023 | |
| Currax Pharmaceuticals LLC | $17.27 | 2023 | Nexlizet, Contrave, Nexletol |
| Kowa Pharmaceuticals America, INC. | $17.23 | 2023 | Seglentis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.97 | 2023 | Caplyta |
| Astellas Pharma US INC | $15.63 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $13.46 | 2023 | Vaxneuvance, Proquad, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.